JP5079961B2 - イレウスの治療及び予防のための新規な方法 - Google Patents

イレウスの治療及び予防のための新規な方法 Download PDF

Info

Publication number
JP5079961B2
JP5079961B2 JP2001543508A JP2001543508A JP5079961B2 JP 5079961 B2 JP5079961 B2 JP 5079961B2 JP 2001543508 A JP2001543508 A JP 2001543508A JP 2001543508 A JP2001543508 A JP 2001543508A JP 5079961 B2 JP5079961 B2 JP 5079961B2
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
hydrogen
substituted
cycloalkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001543508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003517476A (ja
JP2003517476A5 (cg-RX-API-DMAC7.html
Inventor
ファーラー,ジョン・ジェイ
スキード,ピーター・ジェイ
シュミット,ウィリアム・ケイ
カーペンター,ランダール・エル
Original Assignee
アドラー コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドラー コーポレーション filed Critical アドラー コーポレーション
Publication of JP2003517476A publication Critical patent/JP2003517476A/ja
Publication of JP2003517476A5 publication Critical patent/JP2003517476A5/ja
Application granted granted Critical
Publication of JP5079961B2 publication Critical patent/JP5079961B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2001543508A 1999-11-29 2000-11-29 イレウスの治療及び予防のための新規な方法 Expired - Fee Related JP5079961B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45092099A 1999-11-29 1999-11-29
US09/450,920 1999-11-29
PCT/US2000/042313 WO2001042207A2 (en) 1999-11-29 2000-11-29 Novel methods for the treatment and prevention of ileus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012092605A Division JP5460771B2 (ja) 1999-11-29 2012-04-16 イレウスの治療及び予防のための新規な方法

Publications (3)

Publication Number Publication Date
JP2003517476A JP2003517476A (ja) 2003-05-27
JP2003517476A5 JP2003517476A5 (cg-RX-API-DMAC7.html) 2008-01-31
JP5079961B2 true JP5079961B2 (ja) 2012-11-21

Family

ID=23790061

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001543508A Expired - Fee Related JP5079961B2 (ja) 1999-11-29 2000-11-29 イレウスの治療及び予防のための新規な方法
JP2012092605A Expired - Fee Related JP5460771B2 (ja) 1999-11-29 2012-04-16 イレウスの治療及び予防のための新規な方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012092605A Expired - Fee Related JP5460771B2 (ja) 1999-11-29 2012-04-16 イレウスの治療及び予防のための新規な方法

Country Status (14)

Country Link
EP (1) EP1244448B1 (cg-RX-API-DMAC7.html)
JP (2) JP5079961B2 (cg-RX-API-DMAC7.html)
AT (1) ATE432076T1 (cg-RX-API-DMAC7.html)
AU (2) AU780738B2 (cg-RX-API-DMAC7.html)
CA (1) CA2393141C (cg-RX-API-DMAC7.html)
CY (1) CY1109264T1 (cg-RX-API-DMAC7.html)
DE (1) DE60042282D1 (cg-RX-API-DMAC7.html)
DK (1) DK1244448T3 (cg-RX-API-DMAC7.html)
ES (1) ES2329004T3 (cg-RX-API-DMAC7.html)
IL (2) IL149650A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02005336A (cg-RX-API-DMAC7.html)
NZ (1) NZ518684A (cg-RX-API-DMAC7.html)
PT (1) PT1244448E (cg-RX-API-DMAC7.html)
WO (1) WO2001042207A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
MX2007010833A (es) 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
CN101426481B (zh) 2006-04-21 2012-12-05 帝斯曼知识产权资产管理有限公司 阿片受体拮抗剂的用途
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
WO2008121348A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
RU2455943C1 (ru) * 2011-02-01 2012-07-20 Государственное образовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ лечения обтурационной формы острой спаечной тонкокишечной непроходимости

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1420015B1 (de) * 1959-10-16 1971-08-26 Boehringer Sohn Ingelheim 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
FR2514644A1 (fr) * 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
WO1983003197A1 (en) * 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US4730048A (en) * 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds

Also Published As

Publication number Publication date
NZ518684A (en) 2003-11-28
PT1244448E (pt) 2009-06-30
WO2001042207A3 (en) 2002-05-02
DK1244448T3 (da) 2009-08-17
DE60042282D1 (de) 2009-07-09
ES2329004T3 (es) 2009-11-20
JP2012162560A (ja) 2012-08-30
CA2393141A1 (en) 2001-06-14
EP1244448A2 (en) 2002-10-02
MXPA02005336A (es) 2003-01-28
AU2005203041B2 (en) 2009-01-08
EP1244448B1 (en) 2009-05-27
EP1244448A4 (en) 2003-06-25
ATE432076T1 (de) 2009-06-15
CY1109264T1 (el) 2014-07-02
IL149650A (en) 2011-02-28
WO2001042207A2 (en) 2001-06-14
AU2005203041A1 (en) 2005-08-04
JP5460771B2 (ja) 2014-04-02
IL149650A0 (en) 2002-11-10
CA2393141C (en) 2013-08-13
AU780738B2 (en) 2005-04-14
JP2003517476A (ja) 2003-05-27
AU3970501A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
JP5460771B2 (ja) イレウスの治療及び予防のための新規な方法
US6469030B2 (en) Methods for the treatment and prevention of ileus
US6451806B2 (en) Methods and compositions involving opioids and antagonists thereof
AU784541B2 (en) Novel methods and compositions involving opioids and antagonists thereof
US8598207B2 (en) Compositions containing opioid antagonists
US20150126554A1 (en) Methods of preventing and treating gastrointestinal dysfunction
WO2001041705A2 (en) Novel methods for the treatment and prevention of dizziness and pruritus
JP5719773B2 (ja) 末梢オピオイド受容体アンタゴニストおよびその使用
US20150150819A1 (en) Compositions containing opioid antagonists
JP3436701B2 (ja) 掻痒症の治療法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110506

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110801

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110905

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120416

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120801

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120830

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150907

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees